Ordering and Support
Ordering and Support
Ordering and
Support
Ordering and Support
For information about ordering CYSTARAN®, please contact our partner, AllianceRx Walgreens Pharmacy:
PHONE: 1-877-534-9627
Healthcare providers, please click here to access the CYSTARAN prescription and enrollment form.
Stay Updated about CYSTARAN
If you would like to be added to our contact list for updates regarding CYSTARAN (cysteamine ophthalmic solution) 0.44% as well as other medical or product updates, or would like to be contacted by a Leadiant Biosciences, Inc. representative, please select from the following and complete the contact form below:
CYSTARAN®, A Crystal-Clear Solution in an Easy-to-Use Bottle
To treat corneal crystals in patients with cystinosis.
Contact AllianceRx Walgreens Pharmacy at 1-877-534-9627 to order.
CYSTARAN®, A Crystal-Clear Solution in an Easy-to-Use Bottle
To treat corneal crystals in patients with cystinosis.
Contact AllianceRx Walgreens Pharmacy at 1-877-534-9627 to order.
Patient Support Services
We recognize that patient needs extend far beyond medicine. Our commitment to medication access begins with our experienced and passionate team that knows how to deliver treatments to patients who need them. Our advocacy team helps patients access our products by working closely with patient advocacy groups and through patient assistance and reimbursement programs for eligible patients.
Navigating insurance coverage and reimbursement can be challenging for patients and healthcare providers. Some patients may be eligible for patient assistance programs or co-pay assistance programs. Leadiant Biosciences, Inc., offers patient support services through our partner, AllianceRx Walgreens Prime Specialty Pharmacy, to aid patients, caregivers, and healthcare providers with coverage and reimbursement concerns. Eligibility rules apply and are subject to change. Our partner also offers dedicated case managers for each patient who will support the patient immediately and over time, providing a broad range of services from disease education to finding access solutions to working with their insurance companies.
For more information about patient assistance or ordering, contact AllianceRx Walgreens Prime Specialty Pharmacy at 1-877-534-9627.
Adverse Event Reporting
To report an adverse event, call 1-888-393-4584.
You are encouraged to report adverse events to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Medical Information
Phone: 1-866-634-2765
E-mail: leadiant@tmacmail.com
Corporate Contact Information
Leadiant Biosciences, Inc.
530 Gaither Road,. Ste. 300
Rockville, MD 20850
Phone:
Fax:
E-mail:
INDICATION & IMPORTANT SAFETY INFORMATION
CYSTARAN® (CYSTEAMINE OPHTHALMIC SOLUTION) 0.44% is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.
IMPORTANT SAFETY INFORMATION
- To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.
- There have been reports of benign intracranial hypertension (or pseudotumor cerebri) associated with oral cysteamine treatment that has resolved with the addition of diuretic therapy. There have also been reports associated with ophthalmic use of cysteamine; however, all of these patients were on concurrent oral cysteamine.
- CYSTARAN contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration.
- CYSTARAN is for topical ophthalmic use only.
- The most frequently reported ocular adverse reactions occurring in ≥ 10% of patients were sensitivity to light, redness, and eye pain/irritation, headache and visual field defects.
Please refer to CYSTARAN’s full Prescribing Information, available here.
INDICATION & IMPORTANT SAFETY INFORMATION
CYSTARAN® (CYSTEAMINE OPHTHALMIC SOLUTION) 0.44% is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.
